Abbisko's anti-tumor targeted drug Bejimai Phase III study results published in The Lancet
Abbisko-B (02256.HK) officially published the results of its self-developed novel, oral, highly selective, and efficient small molecule CSF-1R inhibitor, Beijiemai (ABSK021, Pimitinib Hydrochloride Capsules), in the international medical journal The Lancet on March 5 (Western European time).
The company stated that the MANEUVER study included 94 subjects across more than 30 clinical centers worldwide, with over half of the patients being from outside China. The results showed that Beijiemai achieved significant efficacy in treating patients with tenosynovial giant cell tumors (TGCT) and overall demonstrated good safety characteristics, indicating its potential in the treatment of related indications
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments